RK Capital Management LLC grew its position in Teligent, Inc. (NASDAQ:TLGT) by 16.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 583,739 shares of the company’s stock after buying an additional 83,122 shares during the period. RK Capital Management LLC owned approximately 1.09% of Teligent worth $3,917,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Summit Creek Advisors LLC grew its stake in shares of Teligent by 15.6% in the third quarter. Summit Creek Advisors LLC now owns 795,853 shares of the company’s stock worth $5,340,000 after acquiring an additional 107,245 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Teligent in the second quarter worth approximately $51,431,000. Argent Capital Management LLC bought a new stake in shares of Teligent in the second quarter worth approximately $3,590,000. JPMorgan Chase & Co. grew its stake in shares of Teligent by 99.5% in the second quarter. JPMorgan Chase & Co. now owns 59,773 shares of the company’s stock worth $547,000 after acquiring an additional 29,816 shares during the period. Finally, FMR LLC bought a new stake in shares of Teligent in the second quarter worth approximately $6,543,000. Hedge funds and other institutional investors own 70.82% of the company’s stock.

Shares of Teligent, Inc. (TLGT) opened at $3.98 on Friday. The company has a current ratio of 3.28, a quick ratio of 2.71 and a debt-to-equity ratio of 2.23. Teligent, Inc. has a 12 month low of $2.82 and a 12 month high of $9.54.

Teligent (NASDAQ:TLGT) last announced its earnings results on Monday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.07). The business had revenue of $13.65 million for the quarter, compared to the consensus estimate of $19.12 million. Teligent had a negative net margin of 16.95% and a negative return on equity of 6.51%. The business’s quarterly revenue was down 15.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.01 earnings per share. equities analysts expect that Teligent, Inc. will post -0.2 EPS for the current fiscal year.

A number of analysts have recently commented on the stock. Zacks Investment Research lowered shares of Teligent from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 11th. Canaccord Genuity lowered shares of Teligent from a “buy” rating to a “hold” rating and reduced their price target for the stock from $9.00 to $5.00 in a research note on Tuesday, November 7th. TheStreet lowered shares of Teligent from a “c-” rating to a “d+” rating in a research note on Wednesday, November 1st. Roth Capital set a $9.00 price target on shares of Teligent and gave the stock a “buy” rating in a research note on Wednesday, August 23rd. Finally, Deutsche Bank reduced their price target on shares of Teligent from $9.00 to $8.00 and set a “hold” rating for the company in a research note on Monday, August 14th. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. Teligent currently has a consensus rating of “Hold” and an average price target of $7.33.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/12/02/teligent-inc-tlgt-holdings-lifted-by-rk-capital-management-llc.html.

Teligent Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Want to see what other hedge funds are holding TLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teligent, Inc. (NASDAQ:TLGT).

Institutional Ownership by Quarter for Teligent (NASDAQ:TLGT)

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.